335 related articles for article (PubMed ID: 12507908)
1. Dysregulation of the annexin family protein family is associated with prostate cancer progression.
Xin W; Rhodes DR; Ingold C; Chinnaiyan AM; Rubin MA
Am J Pathol; 2003 Jan; 162(1):255-61. PubMed ID: 12507908
[TBL] [Abstract][Full Text] [Related]
2. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
4. Localization of annexins I, II, IV and VII in whole prostate sections from radical prostatectomy patients.
Lehnigk U; Zimmermann U; Woenckhaus C; Giebel J
Histol Histopathol; 2005 Jul; 20(3):673-80. PubMed ID: 15944914
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of annexin A10 in gastric cancer and its overexpression in tumor cell growth suppression.
Kim JK; Kim PJ; Jung KH; Noh JH; Eun JW; Bae HJ; Xie HJ; Shan JM; Ping WY; Park WS; Lee JY; Nam SW
Oncol Rep; 2010 Sep; 24(3):607-12. PubMed ID: 20664964
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
7. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
8. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
9. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract][Full Text] [Related]
10. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
11. Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure.
Song G; Campos B; Wagoner LE; Dedman JR; Walsh RA
J Mol Cell Cardiol; 1998 Mar; 30(3):443-51. PubMed ID: 9515022
[TBL] [Abstract][Full Text] [Related]
12. ANXA7 expression represents hormone-relevant tumor suppression in different cancers.
Srivastava M; Torosyan Y; Raffeld M; Eidelman O; Pollard HB; Bubendorf L
Int J Cancer; 2007 Dec; 121(12):2628-36. PubMed ID: 17708571
[TBL] [Abstract][Full Text] [Related]
13. Frequent down-regulation of ABC transporter genes in prostate cancer.
Demidenko R; Razanauskas D; Daniunaite K; Lazutka JR; Jankevicius F; Jarmalaite S
BMC Cancer; 2015 Oct; 15():683. PubMed ID: 26459268
[TBL] [Abstract][Full Text] [Related]
14. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y
J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
16. Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis.
Huang W; Eickhoff JC; Mehraein-Ghomi F; Church DR; Wilding G; Basu HS
Prostate; 2015 Aug; 75(11):1150-9. PubMed ID: 25893668
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
20. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
